Not only is the biotech trading at a discount to its fundamental value, but it's key product is about to be commercialised and the firm could find itself a takeover target. Speculation is that its licencing partner, pharmaceutical giant Eli Lilly, will move when Acrux receives the final approval from US regulators for its spray-on testosterone product Axiron before March next year. At that point Eli Lilly has to fork out $U87 million ($89 Million) to Acrux. Brokers covering the stock rate it a "BUY", with an average price target of $3.46.
Add to My Watchlist
What is My Watchlist?
